International Life Sciences and Healthcare Law Firm

With big deals fuelling record levels of M&A activity, a steady stream of innovative and disruptive technologies, new and increasingly complex regulatory challenges and a thriving start-up community...

We were delighted to bring you this year’s Forum, “Blurring Boundaries - Exploring the convergence of life sciences and law”, from Amsterdam. The theme “Blurring Boundaries - Exploring the convergence of life sciences and law” aimed to:Uncover the latest breakthroughs: Dive into the forefront of life sciences advances, including biotechnology, genetics, pharmaceuticals, and medical devicesAddress the regulatory gap: Engage in interactive workshops to bridge the divide between rapid innovation and the development of legal frame­work­sNav­ig­ate global challenges: Explore the impact of globalisation, ethical considerations, privacy concerns, and societal implications on the life sciences sectorFoster collaboration: Connect with legal and scientific minds, exchange ideas, and build valuable re­la­tion­shipsP­resent­a­tions were delivered by fantastic industry speakers, including Annemiek Verkamman (Managing Director, Hollandbio), Charida Dorder (Member of the Dutch AI Coalition), Wouter Boon (Associate Professor, Utrecht University) and Marc Kaptein (Medical Director, Pfizer), as they shared their expertise, thoughts and insights on how the sector is “Blurring Boundaries”. We were also joined by Simon Neill (Senior Legal Director) at Johnson & John­son and Joep Rijnierse (Senior Medical Director) at Amgen in our workshops. This webpage has been designed to keep you updated on the Forum, our speakers, as well as provide you with the useful resources complementing the theme “Blurring Boundaries - Exploring the convergence of life sciences and law”. You will also find on this page details on how to stay connected with CMS through our upcoming webinar series, On the Pulse Webinar Series 2023 - Autumn (cms. law); free eAlert service, Law-Now; and social media channels.

The Life Sciences and Healthcare Sector is highly tech­no­logy-driv­en and an increasingly dynamic approach is taken when adopting busi­ness-crit­ic­al technologies. This sector’s above-average uptake in technology is reflected in its prioritisation of measures against IT failure. However, the sector is often underprepared for technology risks, with many businesses still not having processes in place to manage key risks despite current and future concerns around disputes arising from this area. This report is a deep dive into data first produced for the report Technology Transformation: Managing Risks in a Changing Landscape. This saw over 500 people surveyed from multiple industries across the world. Here we look in detail at the 75 respondents from the Life Sciences and Healthcare sector, and their perspectives on the risks associated with busi­ness-crit­ic­al technologies, including emerging technologies. Download the Technology Transformation Life Sciences and Healthcare report now to read about:Drivers of technology adoption in the Life Sciences and Healthcare sectorNew risks emerging and traditional barriers to risk man­age­ment­Cur­rent technology risks in the Life Sciences and Healthcare sectorFuture risks, including IP concerns and AIPreferred approaches to technology dispute resolution for the Life Sciences and Healthcare sector